Особенности врожденного иммунитета при вирусных инфекциях

03.02.2012
  1. Li Н., Willlngham S., Ting J., Re F. Cutting edge: Inflammasome activation by alum and alum's adjuvant effect are mediated bu NLRP3 // J. Immunol. 2008. V. 181. R 17 - 21.
  2. Lin M., Zhan Y., Villadangos J., Lew A. The cell biology of cross-presentation and the role of dendritic cell subsets // Immunology and Cell Biology. 2008. V. 86. R 353 - 362.
  3. Liu Y., Chen H., Sun Y., Chen F.A. Antiviral role of toll-like receptors and cytokines against the new 2009 H1N1 virus intection // Mol. Biol. ReR 2011. V. 38. R 2869 - 2874.
  4. Lopez C, Moltedo В., Alexopoulou L. et al. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses // J. Immunol. 2004. v. 173. R 6882 - 6889.
  5. Lund J., Alexopoulou L., Sato A et al. Recognition of single-stranded RNA-viruses by Toll-like receptor 7 // Proc. Natl. Acad. Sci. USA. 2004. V. 101. R 5598 - 5603.
  6. Mangan R, Harrington L., O'Quinn D. et al. Transforming growth factor-fl induces development of the Thi7 lineage // Nature. 2006. V. 441. R 231 - 234.
  7. Manicasssamy S., Pulendran B. Modulation of adaptive immunity with Toll-like receptors // Seminars in Immunology. 2009. V. 21. R185 - 193.
  8. McCormack S., Tilzey A., Carmichael A. et al. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp 120W61D derived from dual tropic R5X4 Hiv-1ACH320 // Vaccine. 2000. V. 18. R1166 -1177.
  9. McSorley S., Ehst В., Yu Y et al. Bacterial flagellin is an effective adjuvant for CD4-I-T cells in vivo // J. Immunol. 2002. V. 169. R 3914 - 3919.
  10. Mosca P., Tritto E., Muzzi A. et al. Molecular and cellular signatures of human vaccine adjuvants // Proc. Natl. Acad. Sci. USA 2008. V. 105. R10501 - 10506.
  11. Navabi H., Jasa N.. Reece A. et al. A clinical grade poly l:C-analogue (Ampligen) promotes optimal DC maturation and Thl-type T cell responses of healthy donors and cancer patients in vitro // Vaccine. 2009. V. 27. R107 - 115.
  12. Nguyen Т., Lee J., Song B. et al. Induction of Inflammatory cytokines and toll-like receptors In chickens infected with avian H9N2 influenza virus // Vet. Res. 2011. V. 42. R 64 - 72.
  13. Obi N.. Hayashi K., Miyahara T. et al. Inhibitory effect of TNF-alpha produced by macrophages stimulated with grifola frondosa extract (ME) on the growth of Influenza А/ Aichi/2/68 virus in MDCK cells // Am. J. Chin. Med. 2008. V. 36. R1171 - 1183.
  14. O'Hagan D., De Grigono E. The path to a successful vaccine adjuvant - the long and winding road // Drug. Discov Today. 2009. V. 14. R 541 - 551.
  15. Perrone L, Plowden J., Garcia-Sastre A. et al. H5N1 and 1918 pandemic influenza virus Infection results in early and excessive Inflltration of macrophages and neutrophils In the lungs of mice // PLoS Pathog. 2008. V 4. R elOOO -1115.
  16. Querec Т., Bennouna S., Alkan S. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7,8 and 9 to stimulate polyvalent Immunity // JEM. 2006. V. 203. R 413 - 424.
  17. Quinlivan M., Nelly M., Prendergast M. etal. Proinflammatory and antiviral cytokine expression in vaccinated and unvaccinated horses exposed to equine influenza virus // Vaccine. 2007. V. 25. R 7056 - 7064.
  18. Romagnani S. Human Thl7 cells // Arthritis Research and Therapy 2008. V. 10. R 230 - 232.
  19. Sadler A., Williams B. Interferon-Inducible antiviral effectors // Nat. Rev. Immunol. 2008. v. 8. R 559-568.
  20. Sanders C, Franchl L., Yarovinsky F. et al. Induction of adaptive immunity by flagellin does not require robust activation of innate immunity // Eur. J. Immunol. 2009. V. 39. R 359 - 371.
  21. 8Ьаф F., Ruane D., Claass B. et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome // Proc. Natl. Acad. Sci. USA 2009. V 106. R 870 - 875.
  22. Schmidt C. Clinical setbacks for toll-like receptor 9 agonists in cancer // Nat. Blotech-nol. 2007. V.25. P825, 826.
  23. Shen E., Li L., Feng L. et al. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA // Cellular & Molecular Immunology. 2007. V. 4. R 113 - 120.
  24. Shi Y, Evans J.E., Rock K.L. Molecular identiflcation of a danger signal that alerts the immune system to dying cells // Nature. 2003. V. 425. R 516 - 521.
  25. Schinya K., Okamura Т., Sueta 8. et al. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic Influenza viruses // J. Virol. 2011. V 8. R 97-104.
  26. See S., Lee K., Byun Y. et al. Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine // Vaccine. 2007. V 25. R 8067 - 8076.
  27. Smith-Garvin J., KoretzkyG., Jordan M.T-cell activation//Annual Review of Immunology. 2009. V 27. R 591-619.
  28. Thitithanyanont A., Engerlng A., Uiprasertkul M. et al. Antiviral Immune responses in H5N1-Infected human lung tissue and possible mechanisms underlying the hyper-production of interferon-inducible protein IP-10 // Biochem. Biophys. Res. Commun. 2010. V 398. R 752-758.
  29. Teijaro J., Walsh K., Cahalan 8. et al. Endothelial cells are central orchestra-tors of cytokine ampliflcation during influenza virus infection // Cell. 2011. V. 46. R 980 - 991.
  30. Ting J., Willlngham S., Bergstralh D. NLR at the intersection of cell death and immunity // Nat. Rev. Immunol. 2008. V 8. R 372 - 379.
  31. Trumpheller C, Caskey M., Nchinda G. et al. The microbial mimic poly l:C induces durable and protective CD4+ T cell immunity together with dendritic cell targeted vaccine // Proc. Natl. Acad. Sci. USA 2008. V 105. P. 2574 - 2579.
  32. Tscherne D., Garcia-Sastre A. Virulence determinants of pandemic influenza viruses // J. of Clinic Investigations. 2011. V 121. R 6 - 13.
  33. Tuvim M., Evans S., Clement C. et al. Augmented lung inflammation protects against influenza A pneumonia // PloS One. 2009. V 4. R 4176 - 4182.
  34. Van Campen H. Influenza A virus replication is inhibited by tumor necrosis factor alpha in vitro II Arch. Virol. 1994. V 136. R 439 - 446.
  35. Wang J., Bowen G., Padden C. et al. Toll-like receptor-mediated activation of neutrophils by influenza A virus // Blood. 2008. V 112. R 2028 - 2034.
  36. Wong J., Christopher M., Vlswanathan S. et al. Activation of toll-like signaling pathway for protection against influenza virus infection // Vaccine. 2009. V. 27. R 3481-3483.
  37. Wong J., Christopher M., Vlswanathan 8. et al. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza virus // Current Pharmaceutical Design. 2009. V 15. R 1269-1274.
  38. Xing Z., Cardona C, Li J. et al. Modulation of the immune responses in chickens by low-pathogenicity avian influenza virus H9N2 // J. Gen. Virol. 2008. V. 89. R 1288 - 1299.
  39. Yoneyama M., Kikuchi M., Natsukava T. et al. The RNA helicase RIG-1 has an essential function in double-stranded RNA-induced innate antiviral responses // Nature immunology. 2004. V 5. R 730 - 737.
  40. Yoneyama M., Fujita T. Function of RIG-l-like receptors in antiviral innate immunity// J. Biol. Chemistry. 2007. V 282. R 15315 - 15318.
  41. Zarember K.A., Godowski PJ. Tissue expressionof human Toll-like receptors and differential regulation of Toll-like receptors mRNA in leukocytes in response to microbes, their products and cytokines // J. of Immunol. 2002. V 168. R 554 - 561.